The patients in the MFR group reported a 53.3 % reduction in their pain and 29.7 % reduction in functional disability as shown in the MPQ and QBPDS scores in week 8 , whereas patients in the control group reported a 26.1 % and 9.8 % reduction in their MPQ and QBPDS scores in week 8 , which persisted as a 43.6 % reduction of pain and 22.7 % reduction of functional disability in the follow-up at week 12 in the MFR group compared to the baseline .